PureTech Health (LON:PRTC) Hits New 1-Year Low - Should You Sell?

PureTech Health plc (LON:PRTC - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as GBX 123.20 ($1.59) and last traded at GBX 135.40 ($1.75), with a volume of 26766676 shares traded. The stock had previously closed at GBX 127.20 ($1.64).

Analysts Set New Price Targets

Separately, Jefferies Financial Group reissued a "buy" rating and set a GBX 455 ($5.88) price target on shares of PureTech Health in a research report on Monday, December 16th.

PureTech Health Price Performance

The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The business's 50 day moving average is GBX 139.75 and its 200-day moving average is GBX 149.82. The firm has a market capitalization of £431.35 million, a P/E ratio of -5.89 and a beta of 1.02.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.